spec sheet10 rows
JNJ-54717793 janssen's brain-penetrant selective orexin-1 receptor antagonist (~50-fold OX1 over OX2); a research tool that blunts panic/anxiety responses in rats without sedating them, illustrating the anti-anxiety angle of OX1 blockade.
- selective OX1 block with ~50-fold selectivity over OX2
- attenuates panic-like responses without sedation in preclinical models
- clean demonstration of the OX1 = stress/panic, OX2 = sleep division
- non-sedating by design, but efficacy in humans unproven
Overview
the anxiety-focused cousin. JNJ-54717793 selectively blocks OX1 and, tellingly, barely changes normal sleep; instead it dampens panic-like reactions to co2 and sodium lactate in rats. it is a tool compound, not a drug, but it cleanly shows what selective OX1 antagonism is good for: stress and panic, not sleep.
- JNJ-54717793 barely affects normal sleep, which is exactly what you expect from a selective OX1 blocker; OX2 is the sleep receptor.
- in OX2-knockout mice it selectively promoted REM sleep, a clean way to prove it was actually hitting OX1 in the brain.
- it blocked panic-like responses to co2 and sodium lactate in rats without sedating them, supporting OX1 antagonism as a non-sedating anti-anxiety strategy.
Mechanism
JNJ-54717793 is a high-affinity, brain-penetrant selective OX1 receptor , about 50-fold selective for OX1R over OX2R (bonaventure 2017). neurons in the perifornical/lateral fire hard in response to anxiogenic and panicogenic stimuli and project into fear and panic circuitry, and OX1R is the receptor most implicated in that stress/panic response. consistent with the OX1 = stress, OX2 = sleep division of labor, JNJ-54717793 had minimal effect on spontaneous sleep in normal rats and wild-type mice, but in OX2-knockout mice it selectively promoted rem sleep (confirming target engagement), and it attenuated co2- and sodium-lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity. that profile, anti-panic without sedation, is the therapeutic thesis for selective OX1 antagonism in anxiety disorders.
receptor fingerprint
OX1R (-1 / HCRTR1)selective competitive antagonist (~50x over OX2)
OX2R (-2 / HCRTR2)much weaker (spared)
Safetyrisks and cautions, not medical advice
investigational research compound; no human safety profile. in the preclinical work it did not cause sedation or disturb baseline locomotor/autonomic activity at anti-panic doses, which is the notable point (bonaventure 2017). not available as a medicine.
History
developed at janssen research & development as a selective OX1 tool/candidate to test whether OX1 antagonism could treat anxiety and panic; the defining paper (bonaventure 2017, frontiers in pharmacology) used two rat panic-provocation models (hypercapnia and sodium lactate after chronic gaba synthesis inhibition in the perifornical hypothalamus). it belongs to the broader effort, alongside idorsia's nivasorexant, to develop selective OX1 blockade for non-sleep indications.
Reputation
a well-regarded preclinical proof-of-concept for OX1-selective anxiolysis; it is cited whenever people argue that orexin drugs could treat panic/anxiety without sedation. it has no clinical standing and is a research tool.
Subjective profileweighing the evidence above
A research tool, and a good one; it separated the panic side of orexin signaling from the sleep side without sedating the animals. There is no human data, nothing available and nothing to use here, only a mechanism worth understanding.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
is JNJ-54717793 a sleep drug?
no. it selectively blocks OX1, which is not the sleep receptor, so it has minimal effect on normal sleep. its interesting activity is anti-panic/anti-anxiety in preclinical models, without sedation.
can i take it?
no; it is a preclinical research tool compound with no human data and no approved use. it is not available as a medicine.
what does it tell us about orexin biology?
it neatly separates the two receptors: blocking OX1 dampened panic responses to co2 and sodium lactate in rats but left normal sleep alone, while OX2 handles sleep. that is the basis for pursuing OX1 blockers for anxiety rather than insomnia.
how is it different from nivasorexant?
both are selective OX1 antagonists (1-SORAs). nivasorexant (idorsia) actually reached human phase 2 for binge eating; JNJ-54717793 (janssen) is a preclinical tool focused on panic/anxiety models. same mechanism class, different developers and stage.
Limitations of the evidence
- no human safety data (research compound)
Adverse effects
- non-sedating by design, but efficacy in humans unproven